Buscar
ProKidney Corp
PROKAñadir a la lista de seguimiento
1.680USD
+0.030+1.82%
Cierre 09-24 16:00（ET）
507.46MCap. mercado
PérdidaP/E TTM
Acerca de ProKidney Corp Compañía
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Perfil de ProKidney Corp
Símbolo de cotizaciónPROK
Nombre de la empresaProkidney Corp
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoCulleton (Bruce)
Número de empleados204
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 30
Dirección2000 Frontis Plaza Blvd
CiudadWINSTON-SALEM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27103
Teléfono13369997028
Sitio Webhttps://prokidney.com/
Símbolo de cotizaciónPROK
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoCulleton (Bruce)
Ejecutivos de ProKidney Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Lead Independent Director
Lead Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J.G. Pereira, M.D.
Dr. Brian J.G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Lead Independent Director
Lead Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ProKidney Corp?
Los cinco principales accionistas de ProKidney Corp son: Dr. Uma Sinha, Ph.D.
¿Cuántas instituciones poseen acciones de ProKidney Corp (PROK)?
A fecha de 2026Q1, 181 instituciones poseen acciones de ProKidney Corp, con un valor de mercado combinado de aproximadamente 50.49M, lo que representa el 35.56% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 4723430.00.